News | April 29, 2009

Long-Term Cardiovascular Study Selects OpenClinica Enterprise Management Solution

April 29, 2009 - The Abuja Heart Study, a long-term cardiovascular study involving up to 10,000 patients from multiple sites across Nigeria, will employ the OpenClinica Enterprise for electronic data capture and clinical data management.

Data is not yet available to determine the magnitude and social burden of cardiovascular disease or the distribution within the population of many countries, including Nigeria, where it is expected to become a leading cause of death within the next 10 to 15 years.

In many ways analogous to the well-known Framingham Heart Study, the Abuja Heart Study will help scientists understand the role socio-cultural and hereditary factors play in a specific population in order to adopt targeted policies for prevention and control.

OpenClinica is open source, Web-based clinical trials software for electronic data capture (EDC) and clinical data management (CDM) that reportedly facilitates study protocol configuration, data collection via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible and modular platform.

"This study has some specific requirements for its electronic data capture and data management needs," said Study Director Uchenna Onyeachom. "We require a lightweight, standards-based, and regulatory compliant system that can function well in resource constrained settings and is intuitive to remote users with minimal training. The flexible OpenClinica technology and enterprise open source approach from Akaza provide us with these benefits and give us the necessary assurance that many years from now our study will still be run with robust and well-supported software."

Collaborators on Abuja Heart Study include the Harvard Clinical Research Institute, Byrne Healthcare, Federal Ministry of Health Nigeria and Healthsystem Plus.

For more information: http://www.openclinica.org., http://abujaheartstudy.org.


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now